European Journal of Cancer
Volume 39, Issue 13 , Pages 1866-1871, September 2003

Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

  • E. Winquist

      Affiliations

    • Division of Medical Oncology, 790 Commissioners Road East, London, Ontario, Canada N6A 4L6
    • Corresponding Author InformationCorresponding author. Tel.: +1-519-685-8600; fax: +1-519-685-8624
    • ,
  • D.S. Ernst

      Affiliations

    • Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    • ,
  • D. Jonker

      Affiliations

    • Division of Medical Oncology, 790 Commissioners Road East, London, Ontario, Canada N6A 4L6
    • ,
  • M.J. Moore

      Affiliations

    • Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    • ,
  • R. Segal

      Affiliations

    • Department of Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Canada
    • ,
  • G. Lockwood

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, Toronto, Canada
    • ,
  • A. Rodgers

      Affiliations

    • Schering Canada Inc, Pointe-Claire, Quebec, Canada

Received 12 December 2002; received in revised form 31 January 2003; accepted 4 April 2003.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • PII: S0959-8049(03)00358-7

    doi:10.1016/S0959-8049(03)00358-7

    European Journal of Cancer
    Volume 39, Issue 13 , Pages 1866-1871, September 2003